You have 9 free searches left this month | for more free features.

surufatinib

Showing 1 - 25 of 39

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)

Not yet recruiting
  • Carcinoma
  • +7 more
  • (no location specified)
Nov 12, 2023

Surufatinib in G3 Neuroendocrine Tumors

Not yet recruiting
  • Neuroendocrine Tumor Grade 3
  • Surufatinib
  • (no location specified)
Aug 2, 2023

Differentiated Thyroid Cancer Trial in Shanghai (surufatinib)

Recruiting
  • Differentiated Thyroid Cancer
  • surufatinib
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 9, 2023

Soft Tissue Sarcoma Adult Trial (Surufatinib)

Not yet recruiting
  • Soft Tissue Sarcoma Adult
  • Surufatinib
  • (no location specified)
Oct 29, 2023

Renal Impairment Trial in Tustin, Orlando (Surufatinib)

Completed
  • Renal Impairment
  • Surufatinib
  • Tustin, California
  • +1 more
Nov 2, 2022

Advanced NSCLC Trial in Guangzhou (Surufatinib, Surufatinib Plus Vinorelbine)

Recruiting
  • Advanced Non-Small Cell Lung Cancer
  • Surufatinib
  • Surufatinib Plus Vinorelbine
  • Guangzhou, Guangdong, China
    Affiliated Cancer Hospital and Institute of Guangzhou Medical Un
Aug 18, 2022

Hepatic Impairment Trial in Tustin, Orlando (Surufatinib)

Completed
  • Hepatic Impairment
  • Surufatinib
  • Tustin, California
  • +1 more
Aug 29, 2022

Ovarian Cancer Trial in Hefei (Pamiparib, Surufatinib)

Recruiting
  • Ovarian Cancer
  • Hefei, Anhui, China
    Anhui Cancer Hospital
Dec 6, 2022

Small Cell Lung Cancer, Angiogenesis, Chemo Effect Trial (Surufatinib, Irinotecan)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Nov 27, 2022

Metastatic Triple-negative Breast Cancer Trial in Wuhan (Surufatinib, Tislelizumab)

Not yet recruiting
  • Metastatic Triple-negative Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Feb 27, 2023

Unresectable Locally Advanced or Metastatic Pancreatic Cancer Trial in Shanghai (surufatinib, KN046, gemcitabine)

Not yet recruiting
  • Unresectable Locally Advanced or Metastatic Pancreatic Cancer
  • surufatinib
  • +3 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Apr 16, 2023

High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

Recruiting
  • High-Risk Localized Soft Tissue Sarcoma
  • Surufatinib
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 20, 2023

Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Pancreatic Carcinoma Trial in Tianjin (Surufatinib, Sintilimab)

Recruiting
  • Neuroendocrine Tumor Grade 3
  • +2 more
  • Tianjin, Tianjin, China
    Rui Liu
Nov 17, 2022

Sarcoma Trial in Guangzhou (Surufatinib)

Recruiting
  • Sarcoma
  • Surufatinib
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Univerisity
May 5, 2022

Pancreatic Tumors Trial in Guangzhou (Surufatinib, TAS-102)

Not yet recruiting
  • Pancreatic Neoplasms
  • Guangzhou, Guangdong, China
    Cancer center of SunYat-sen University
Jul 28, 2022

Pancreatic Tumors Trial in Guangzhou (Surufatinib, Sintilimab, AG)

Not yet recruiting
  • Pancreatic Neoplasms
  • Surufatinib
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer center of SunYat-sen University
Jul 28, 2022

Extensive-Stage Small Cell Lung Cancer Trial in Beijing (Surufatinib, Anti-PD-1/L1)

Not yet recruiting
  • Extensive-Stage Small Cell Lung Cancer
  • Beijing, China
    Chinese PLA General Hospital
Aug 18, 2022

Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
Aug 8, 2022

Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic Trial in Guangzhou (Surufatinib)

Recruiting
  • Adenocarcinoma of Small Intestine
  • +2 more
  • Surufatinib
  • Guangzhou, Guangdong, China
    The Sixth Affiliated Hospital of Sun Yat-sen University
Jul 22, 2022

Neuroendocrine Tumors Trial in United States (Surufatinib)

No longer available
  • Neuroendocrine Tumors
  • Surufatinib
  • Denver, Colorado
  • +10 more
Oct 28, 2022

Tumors Trial in Italy, United States (surufatinib)

Completed
  • Tumors
  • surufatinib
  • Los Angeles, California
  • +11 more
Jan 11, 2023

Hepatocellular Carcinoma Trial in Nanjing (Surufatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Surufatinib
  • Nanjing, Jiangsu, China
    Nanjing Drum tower hospital
Apr 6, 2022

Colorectal Cancer Trial in Hangzhou (Surufatinib, Toripalimab, chemo)

Recruiting
  • Colorectal Cancer
  • Surufatinib
  • +2 more
  • Hangzhou, Zhejiang, China
    First affiliated hospital, Zhejiang University
Feb 26, 2022

Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival Trial in Wuhan (Surufatinib)

Recruiting
  • Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
  • Surufatinib
  • Wuhan, Hubei, China
    Zhongnan Hopital of Wuhan University
Mar 8, 2022

Neuroendocrine Tumor Trial in Beijing (Sintilimab, IBI310, Surufatinib)

Recruiting
  • Neuroendocrine Neoplasm
  • Beijing, Beijing, China
  • +1 more
Dec 7, 2021